AN2 Therapeutics, Inc. SEC filings ANTX
AN2 Therapeutics, Inc. has 384 filings in SEC EDGAR's recent list, going back to Sep 24, 2021. Its latest annual report, Form ARS, was filed on Apr 22, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 11, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 9, 2026 | Jun 3, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 4, 2026 | Jun 4, 2026 |
| 8-K |
Current report
Results of operations
|
May 11, 2026 | May 11, 2026 |
| 8-K |
Current report
Other events
|
Apr 9, 2026 | Apr 9, 2026 |
| 8-K |
Current report
Officer or director change
|
Mar 20, 2026 | Mar 19, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 17, 2026 | Mar 17, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Mar 10, 2026 | Mar 8, 2026 |
| 8-K |
Current report
Officer or director change
|
Jan 29, 2026 | Jan 26, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2025 | Nov 12, 2025 |
| 8-K | Current report | Aug 12, 2025 | Aug 12, 2025 |
| 8-K |
Current report
Unregistered share sale
|
Jun 20, 2025 | Jun 17, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 11, 2025 | Jun 11, 2025 |
| 8-K |
Current report
Shareholder vote results
|
May 27, 2025 | May 22, 2025 |
| 8-K | Current report | May 13, 2025 | May 13, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
May 1, 2025 | May 1, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 25, 2025 | Mar 25, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2024 | Nov 13, 2024 |
| 8-K |
Current report
Officer or director change
|
Nov 5, 2024 | Nov 4, 2024 |
| 8-K |
Current report
Material agreement, Change to shareholder rights, Bylaw or fiscal year change
|
Aug 19, 2024 | Aug 15, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2024 | Aug 13, 2024 |
| 8-K |
Current report
Exit or restructuring costs, Officer or director change, Regulation FD disclosure, Other events
|
Aug 8, 2024 | Aug 7, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 24, 2024 | Jun 19, 2024 |
| 8-K |
Current report
Results of operations
|
May 14, 2024 | May 14, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 28, 2024 | Mar 28, 2024 |
| 8-K |
Current report
Other events
|
Feb 12, 2024 | Feb 12, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2023 | Nov 9, 2023 |
| 8-K |
Current report
Other events
|
Sep 13, 2023 | Sep 13, 2023 |
| 8-K |
Current report
Officer or director change
|
Sep 8, 2023 | Sep 1, 2023 |
| 8-K |
Current report
Material agreement, Other events
|
Aug 16, 2023 | Aug 15, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2023 | Aug 10, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 9, 2023 | Jun 7, 2023 |
| 8-K |
Current report
Results of operations
|
May 11, 2023 | May 11, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 29, 2023 | Mar 29, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2022 | Nov 9, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 6, 2022 | Oct 6, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2022 | Aug 11, 2022 |
| 8-K |
Current report
Other events
|
Jun 29, 2022 | Jun 29, 2022 |
| 8-K |
Current report
Results of operations
|
May 10, 2022 | May 10, 2022 |
| 8-K |
Current report
Officer or director change
|
May 9, 2022 | May 5, 2022 |
Showing 40 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ANTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Menlo Park, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1880438
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.